PAI Pharma has acquired Nexus Pharmaceuticals, adding more than 20 hospital injectable products to its commercial portfolio and expanding its presence in sterile injectable medicines. Nexus specializes in developing and commercializing injectable medicines used in critical care, oncology and other hospital settings, including therapies that have historically faced supply shortages.
The acquisition follows PAI's recent purchase of Nivagen Pharmaceuticals, which added aseptic manufacturing capabilities in Sacramento and expanded its ready-to-use injectable product offering for the hospital market. Together, the acquisitions form part of PAI's strategy to broaden its medicines portfolio and increase its hospital and sterile injectable business alongside its existing oral liquid operations.
Nexus combines pharmaceutical development and analytical expertise with a network of contract manufacturing partners and established relationships across the U.S. hospital market. PAI said the acquired business brings experience in developing and commercializing injectable therapies, along with customer relationships that complement its existing hospital-focused operations and growing sterile injectable portfolio.
PAI, headquartered in Parsippany, New Jersey, is a portfolio company of Olympus Partners that develops, manufactures and markets oral liquid, sterile and ready-to-use pharmaceutical products. The company said combining these operations with Nexus's commercial portfolio will allow it to supply hospitals and healthcare providers with a broader range of medicines across its oral liquid and injectable businesses.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!